Echinacea for cryptosporidiosis in children with weak immune systems
Part of Digestive system, Infections clinical trials.
This trial tests whether the herb echinacea (Immulant) can help treat cryptosporidiosis, a diarrheal infection, in children aged 5 to 12 whose immune systems are weakened. It aims to find a safe and effective treatment for these children.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have a confirmed case of cryptosporidiosis (a diarrheal infection).
- Your child must be between 5 and 12 years old.
- Your child's immune system must be weakened (immunocompromised).
- Your child must not be taking any medications that suppress the immune system.
- Your child must not have had an organ transplant.
- Your child must not have an autoimmune disease (like lupus or rheumatoid arthritis).
- Your child must not be allergic to echinacea or similar plants.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, EDI048, to see how well it works and how safe it is for treating cryptosporidium infection. It is for healthy volunteers who will be intentionally exposed to the infection under controlled conditions.
This study follows children aged 6 months to 5 years with diarrhea caused by Cryptosporidium. It aims to understand how the infection develops over time and how it affects children.
This study tests a medicine called nitazoxanide to treat cryptosporidium, a germ that can cause diarrhea in children. If your child tests positive for this germ, the treatment may help clear the infection.
This study collects tissue and blood samples from people having surgery for echinococcosis. The samples will help develop a better PCR test (a lab test that detects the parasite) so doctors can diagnose the infection more accurately.
This trial measures how anti-infective medicines move through a child’s body while they are in the hospital or during follow-up. The goal is to better understand dosing and drug exposure in critically ill children.
This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.
Hear when a new Cryptosporidium Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.